



Docket No.: PZ003P2  
(PATENT)

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Patent Application of:  
Ruben et al.

Application No.: 09/852,797

Confirmation No.:

Filed: May 11, 2001

Art Unit: 1653

For: Human Secreted Protein HTEEB42 (As  
Amended)

Examiner: H. Robinson

**FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure imposed by 37 C.F.R. § 1.56 to inform the Patent and Trademark Office of all references coming to the attention of each individual associated with the filing or prosecution of the subject application, which are or may be material to the patentability of a claim of the subject application, Attorney for Applicants hereby directs the Examiner's attention to reference M listed on the attached Form PTO/SB/08.

The listed reference is presented so that the Patent and Trademark Office can determine any materiality thereof to the claimed invention. *See*, 37 C.F.R. § 1.104(a) concerning the Examiner's duty to consider and use any such information. Applicants respectfully request that the Examiner make the listed reference of record in the file history of the application, and consider the information contained therein during the prosecution of this application.

Identification of the listed reference is not to be construed as an admission of any individual associated with the filing or prosecution of the subject application that such reference is available as "prior art" against the subject application. Furthermore, Applicants do not waive any rights to take appropriate action to establish patentability over the listed document should it be applied as a reference against the claims of the subject application.

Pursuant to 37 C.F.R. § 1.97(c)(2), the Patent Office will consider this Information Disclosure Statement if filed before the mailing date of a final Office Action under § 1.113, a

03/23/2004 AHAB11 00000142 003425 09852797


01 FC:1806 180.00 BR

Pursuant to 37 C.F.R. § 1.97(c)(2), the Patent Office will consider this Information Disclosure Statement if filed before the mailing date of a final Office Action under §1.113, a notice of allowance under §1.311, or an action that otherwise closes prosecution in this application and accompanied by the fee set forth in § 1.17(p). Accordingly, the required fee of \$180.00 is transmitted herewith with the concurrently filed Fee Transmittal, with the appropriate fee(s).

If any additional fees are deemed necessary, the Patent & Trademark Office is authorized to charge the required fee to Human Genome Sciences, Inc., deposit account no. 08-3425.

Dated: March 22, 2004

Respectfully submitted,

By   
Janet M. Martineau

Registration No.: 46,903  
HUMAN GENOME SCIENCES, INC.  
14200 Shady Grove Road  
Rockville, Maryland 20850  
(301) 315-2723

KKH/JMM/KM/lcc  
Enclosures



PTO/SB/08a/b (06-03)  
Approved for use through 07/31/2003. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>Substitute for form 1449A/B/PTO</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	09/852,797-Conf. #5177
				Filing Date	May 11, 2001
				First Named Inventor	Steven M. Ruben
				Art Unit	1637
				Examiner Name	K. Hordick
Sheet	1	of	1	Attorney Docket Number	PZ003P2

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)					

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	M	CUNNINGHAM et al., "A novel protein with homology to the junctional adhesion molecule," <i>J. Biol. Chem.</i> 275(44):34750-34756 (2000).	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--



PTO/SB/08a/b (06-03)

Approved for use through 07/31/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	09/852,797-Conf. #5177
				Filing Date	May 11, 2001
				First Named Inventor	Steven M. Ruben
				Art Unit	1637
				Examiner Name	K.R. Horlick
Sheet	1	of	2	Attorney Docket Number	PZ003P2

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)				
	A	WO-00/15797-A2	03-23-2000	Genentech, Inc.	61-63; 69-77	
	B	WO-99/14241-A2	03-25-1999	Genentech, Inc.	44-45; 50-55	
	C	WO-99/27098-A2	06-03-1999	Genentech, Inc.		

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	D	CUNNINGHAM et al., "JAM2 Interacts with $\alpha 4\beta 1$ ," <i>J. Biol. Chem.</i> 277(31):27589-27592 (Aug. 2, 2002).	
	E	PALMERI et al., "Vascular Endothelial Junction-associated Molecule, a Novel Member of the Immunoglobulin Superfamily, Is Localized to Intercellular Boundaries of Endothelial Cells," <i>J. Biol. Chem.</i> 275(25):19139-19145 (Jun. 23, 2000).	
	F	LIANG et al., "Vascular Endothelial-Junctional Adhesion Molecule (VE-JAM)/JAM 2 Interacts with T, NK, and Dendritic Cells Through JAM 3," <i>J. Immunol.</i> 168:1618-1626 (2002).	
	G	GenBank Accession No. AL570767, LI et al., "AL57067 Homo sapiens PLACENTA COT 25-NORMALIZED Homo sapiens cDNA clone CS0DI022YK04 3-PRIME, mRNA sequence" (May 31, 2003).	
	H	GenBank Accession No. N90730, HILLIER et al., "za90e09.s1 Soares_fetal_lung_NbHL19W Homo sapiens cDNA clone IMAGE:299848 3', mRNA sequence" (Apr. 3, 1996).	
	I	GenBank Accession No. T89217, HILLIER et al., "ye12c02.r1 Stratagene lung (#937210) Homo sapiens cDNA clone IMAGE:117506 5', mRNA sequence" (Mar. 20, 1995).	
	J	GenBank Accession No. AI556456, BONALDO et al., "UI-R-C2p-rh-g-10-0-UI.s1 UI-R-C2p Rattus norvegicus cDNA clone UI-R-C2p-rh-g-10-0-UI 3', mRNA sequence" (Jul. 5, 1999).	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	09/852,797-Conf. #5177
				Filing Date	May 11, 2001
				First Named Inventor	Steven M. Ruben
				Art Unit	1637
				Examiner Name	K.R. Horlick
				Attorney Docket Number	PZ003P2
Sheet	2	of	2		

K	GenBank Accession No. AA410345, HILLIER et al., "zv12a02.s1 Soares_NhHMPu_S1 Homo sapiens cDNA clone IMAGE:753386 3', mRNA sequence" (May 17, 1997).	
L	GenBank Accession No. BE653351, BONALDO et al., "UI-M-AL1-ahi-d-06-0-UI.r1 NIH_BMAP_MCO_N Mus musculus cDNA clone UI-M-AL1-ahi-d-06-0-UI 5', mRNA sequence" (Sep. 6, 2000).	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--



image

1653

PTO/SB/17 (10-03)

Approved for use through 7/31/2006. OMB 0651-0032

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Patent Work Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

# FEE TRANSMITTAL for FY 2004

Effective 10/01/2003, Patent fees are subject to annual revision.

☐ Applicant claims small entity status. See 37 CFR 1.27

TOTAL AMOUNT OF PAYMENT (\$) 180.00

## Complete if Known

Application Number 09/852,797-Conf. #5177  
Filing Date May 11, 2001  
First Named Inventor Steven M. Ruben  
Examiner Name K. Horlick  
Art Unit 1653  
Attorney Docket No. PZ003P2

## METHOD OF PAYMENT (check all that apply)

☐ Check ☐ Credit Card ☐ Money Order ☐ Other ☐ None

☒ Deposit Account:

Deposit Account Number

08-3425

Deposit Account Name

Human Genome Sciences, Inc.

The Director is authorized to: (check all that apply)

☒ Charge fee(s) indicated below ☒ Credit any overpayments

☒ Charge any additional fee(s) or any underpayment of fee(s)

☐ Charge fee(s) indicated below, except for the filing fee to the above-identified deposit account.

## FEE CALCULATION

### 1. BASIC FILING FEE

Large Entity Small Entity

Fee Code	Fee (\$)	Fee Code	Fee (\$)	Fee Description	Fee Paid
1001	770	2001	385	Utility filing fee	
1002	340	2002	170	Design filing fee	
1003	530	2003	265	Plant filing fee	
1004	770	2004	385	Reissue filing fee	
1005	160	2005	80	Provisional filing fee	

SUBTOTAL (1) (\$) 0.00

### 2. EXTRA CLAIM FEES FOR UTILITY AND REISSUE

Total Claims	Extra Claims	Fee from below	Fee Paid
45	-51 =		
Independent Claims	8	-11 =	
Multiple Dependent			

Large Entity Small Entity

Fee Code	Fee (\$)	Fee Code	Fee (\$)	Fee Description
1202	18	2202	9	Claims in excess of 20
1201	86	2201	43	Independent claims in excess of 3
1203	290	2203	145	Multiple dependent claim, if not paid
1204	86	2204	43	** Reissue independent claims over original patent
1205	18	2205	9	** Reissue claims in excess of 20 and over original patent

SUBTOTAL (2) (\$) 0.00

\*\*or number previously paid, if greater; For Reissues, see above

## FEE CALCULATION (continued)

### 3. ADDITIONAL FEES

Large Entity Fee Code	Large Entity Fee (\$)	Small Entity Fee Code	Small Entity Fee (\$)	Fee Description	Fee Paid
1051	130	2051	65	Surcharge - late filing fee or oath	
1052	50	2052	25	Surcharge - late provisional filing fee or cover sheet.	
1053	130	1053	130	Non-English specification	
1812	2,520	1812	2,520	For filing a request for <i>ex parte</i> reexamination	
1804	920*	1804	920*	Requesting publication of SIR prior to Examiner action	
1805	1,840*	1805	1,840*	Requesting publication of SIR after Examiner action	
1251	110	2251	55	Extension for reply within first month	
1252	420	2252	210	Extension for reply within second month	
1253	950	2253	475	Extension for reply within third month	
1254	1,480	2254	740	Extension for reply within fourth month	
1255	2,010	2255	1,005	Extension for reply within fifth month	
1401	330	2401	165	Notice of Appeal	
1402	330	2402	165	Filing a brief in support of an appeal	
1403	290	2403	145	Request for oral hearing	
1451	1,510	1451	1,510	Petition to institute a public use proceeding	
1452	110	2452	55	Petition to revive - unavoidable	
1453	1,330	2453	665	Petition to revive - unintentional	
1501	1,330	2501	665	Utility issue fee (or reissue)	
1502	480	2502	240	Design issue fee	
1503	640	2503	320	Plant issue fee	
1460	130	1460	130	Petitions to the Commissioner	
1807	50	1807	50	Processing fee under 37 CFR 1.17(q)	
1806	180	1806	180	Submission of Information Disclosure Stmt	180.00
8021	40	8021	40	Recording each patent assignment per property (times number of properties)	
1809	770	2809	385	Filing a submission after final rejection (37 CFR 1.129(a))	
1810	770	2810	385	For each additional invention to be examined (37CFR 1.129(b))	
1801	770	2801	385	Request for Continued Examination (RCE)	
1802	900	1802	900	Request for expedited examination of a design application	

Other fee (specify)

\*Reduced by Basic Filing Fee Paid

SUBTOTAL (3) (\$) 180.00

## SUBMITTED BY

Name (Print/Type) Janet M. Martineau

Registration No. (Attorney/Agent)

46,903

(Complete (if applicable))

Telephone (301) 315-2723

Signature

*Janet M. Martineau*

Date

March 22, 2004